<DOC>
	<DOCNO>NCT00671086</DOCNO>
	<brief_summary>The purpose study determine long-term safety Ramelteon , daily ( QD ) , subject chronic insomnia .</brief_summary>
	<brief_title>Efficacy Ramelteon Subjects With Chronic Insomnia</brief_title>
	<detailed_description>Insomnia characterize difficulty initiate maintain sleep complaint non-restorative non-refreshing sleep . Transient insomnia affect approximately one-third one-half US population , base result 2 survey representative sample adult US population conduct Gallup Organization respondent ask `` ever difficulty sleep . '' Based report `` regular '' `` frequent '' sleep difficulty , result study suggest approximately one-tenth US population experience chronic insomnia . The ideal treatment insomnia would reduce latency onset sleep increase total sleep time , without negative impact sleep architecture without safety concern next-day effect . Ramelteon selective melatonin-1 receptor agonist global development Takeda Chemical Industries , Ltd. , treatment transient chronic insomnia treatment Circadian Rhythm Sleep Disorders . The purpose study obtain data support safety long-term use Ramelteon insomnia , determine whether adverse effect associate extended use . Participation study expect . Participation study anticipate approximately 13 month .</detailed_description>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<criteria>Inclusion Criteria Participant participate allow Ramelteon study complete final visit procedure previous study within 21 day Treatment Initiation Visit study . Females childbearing potential sexually active must agree use adequate contraception , neither pregnant lactating Screening throughout duration study . Investigator believe participant require longterm treatment insomnia . Primary insomnia define Diagnostic Statistical Manual Mental Disorders , 4th Edition Revised least 3 month history daytime complaint ( ) associate disturbed sleep . Subjective sleep latency great equal 45 minute subjective total sleep time le equal 6.5 hour per night least 3 night week Baseline Leadin Period . Habitual bedtime 8:30PM 12:00AM . Body mass index 18 34 , inclusive . Exclusion Criteria Known hypersensitivity Ramelteon related compound , include melatonin . Participated investigational study , and/or take investigational drug within 30 day five halflives prior Day 1 study medication , whichever longer . The exception prior participation allow Ramelteon study . Sleep schedule change require employment ( eg , shift worker ) within three month prior Day 1 study medication , fly across great three time zone within seven day prior screen . Participated weight loss program substantially alter exercise routine within 30 day prior Day 1 study medication . Ever history seizure , sleep apnea , chronic obstructive pulmonary disease , restless leg syndrome , schizophrenia , bipolar disorder , mental retardation , cognitive disorder . History psychiatric disorder ( include anxiety depression ) within past 12 month . History drug addiction drug abuse past 12 month . History alcohol abuse within past 12 month , define Diagnostic Statistical Manual Mental Disorders , 4th Edition Revised and/or regularly consume 4 alcoholic drink per day . Current significant neurological , hepatic , renal , endocrine , cardiovascular , gastrointestinal , pulmonary , hematologic , metabolic disease , unless currently control stable protocolallowed medication 30 day prior Day 1 study medication . Uses tobacco product nightly awakening . Any clinically important abnormal finding determine medical history , physical examination , electrocardiogram , clinical laboratory test , determine investigator . Positive hepatitis panel . Any additional condition ( ) Investigator 's opinion would : affect sleep/wake function prohibit subject completing study , best interest subject participate study . Morning serum cortisol Baseline visit le 7.0 microg per dl . Is required take continue take disallow medication , prescription medication , herbal treatment overthe counter medication , include : Anxiolytics Hypnotics Antidepressants Anticonvulsants Sedating H1 antihistamine Systemic steroid Respiratory stimulant ( eg , theophylline ) Decongestants Overthecounter prescription stimulant Overthecounter prescription diet aids Central nervous system active drug Narcotic analgesic Beta blocker St. John 's Wort Kavakava Gingko biloba Melatonin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Chronic Insomnia</keyword>
	<keyword>DIMS ( Disorders Initiating Maintaining Sleep )</keyword>
	<keyword>Disorders Initiating Maintaining Sleep</keyword>
	<keyword>Insomnia Disorder Sleep Initiation Dysfunction</keyword>
	<keyword>Transient Insomnia</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Sleep Disorders , Intrinsic</keyword>
</DOC>